Shopping Cart
Remove All
Your shopping cart is currently empty
Brontictuzumab (Synonyms: OMP52M5, OMP 52M5, Anti-Human NOTCH1 Recombinant Antibody)
Catalog No. T76785 Copy Product Info
🥰Excellent
Brontictuzumab (OMP 52M5) is a monoclonal antibody that targets Notch1 and inhibits activation of the pathway. It has antitumor activity, inhibits tumor cell proliferation, and can be used in the study of leukemias and lymphomas.
Brontictuzumab
Copy Product Info🥰Excellent
Catalog No. T76785
Synonyms OMP52M5, OMP 52M5, Anti-Human NOTCH1 Recombinant Antibody
Brontictuzumab (OMP 52M5) is a monoclonal antibody that targets Notch1 and inhibits activation of the pathway. It has antitumor activity, inhibits tumor cell proliferation, and can be used in the study of leukemias and lymphomas.
Brontictuzumab
Cas No. 1447814-75-6
Customer service consultation
| Pack Size | Price | USA Stock | Global Stock | Quantity |
|---|---|---|---|---|
| 1 mg | $297 | In Stock | In Stock | |
| 5 mg | $775 | In Stock | In Stock | |
| 10 mg | $1,230 | - | In Stock | |
| 25 mg | $1,830 | - | In Stock | |
| 50 mg | $2,480 | - | In Stock | |
| 100 mg | $3,330 | Inquiry | Inquiry |
For In stock only · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)
Add to Cart
Add to Quotation
For research use only—not for human use. No sales to individuals. Use as intended only.
Batch Information
Select Batch
Purity:98.1% (SDS-PAGE); 97.6% (SEC-HPLC)
Appearance:Liquid
Color:Transparent
Contact us for more batch information
Resource Download
Product Introduction
Bioactivity
Related Conjugates and Formulations
Antigen Details
Chemical Properties
Antibody Information
Storage & Solubility Information
| Description | Brontictuzumab (OMP 52M5) is a monoclonal antibody that targets Notch1 and inhibits activation of the pathway. It has antitumor activity, inhibits tumor cell proliferation, and can be used in the study of leukemias and lymphomas. |
| In vitro | 0-100 μg/mL Brontictuzumab effectively inhibited the activity of Notch1 signaling pathways, including DLL4 and JAG1/2. In HPB-ALL cell line, treatment with 25 μg/mL Brontictuzumab for 4 days significantly reduced the level of Notch1 intracellular structural domain. [1] In MCL cells, treatment with 25 μg/mL Brontictuzumab for 48 hours inhibited DLL4-mediated overexpression of cleaved Notch1. In addition, the increased phosphorylation of MEK and ERK in Mino cells caused by DLL4 stimulation was effectively blocked. [2] |
| In vivo | In the MCL model, 20 mg/kg Brontictuzumab intraperitoneal injection, administered every 4 days, inhibited DLL4-induced Notch1 activation. [2] Intraperitoneal injection of 15 mg/kg Brontictuzumab significantly reduced tumor burden in a T-ALL xenograft model. [3] |
| Synonyms | OMP52M5, OMP 52M5, Anti-Human NOTCH1 Recombinant Antibody |
| Reactivity | Human |
| Application | Functional assay |
| Antibody Type | Monoclonal |
| Formulation | Supplied as a sterile solution in a buffered formulation system (e.g., phosphate-, citrate-, or amino acid-based). Please refer to the CoA for lot-specific composition. |
| Endotoxin | <1.0 EU/mg |
| Conjucates | Unconjugated |
| Gene ID | |
| Uniprot ID | |
| Target | NOTCH1 |
| Molecular Weight | 143.93 kDa |
| Cas No. | 1447814-75-6 |
| Isotype | IgG2SA |
| Storage | store at low temperature | -20°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
Calculator
Keywords
Preview
Related Tags: buy Brontictuzumab | purchase Brontictuzumab | Brontictuzumab cost | order Brontictuzumab | Brontictuzumab in vivo | Brontictuzumab in vitro | Brontictuzumab molecular weight
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.